Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Jul;53(7):554–557. doi: 10.1136/jnnp.53.7.554

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

C Milanese 1, A Salmaggi 1, L La Mantia 1, A Campi 1, M Eoli 1, M Savoiardo 1, G Bianchi 1, A Nespolo 1
PMCID: PMC488128  PMID: 1697334

Abstract

Sixteen patients with clinically definite MS admitted to a double blind randomised controlled trial of intrathecal natural beta-IFN were followed for a mean of 22 months including the six month treatment period. Clinical response, evaluated in terms of relapse frequency and of progression rate, showed an increase in relapse rate in treated patients during the six month treatment period and, overall, no benefit in treated versus placebo patients. Serial evaluations were made of cerebrospinal fluid (CSF) cells, IgG, myelin basic protein and CSF and blood T-cell subsets. A rise in CSF IgG Index, MBP and DR+ cells in IFN-treated patients suggested an activation of intrathecal immune response in treated patients.

Full text

PDF
554

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunda M. J., Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res. 1984 Feb;44(2):597–601. [PubMed] [Google Scholar]
  2. Camenga D. L., Johnson K. P., Alter M., Engelhardt C. D., Fishman P. S., Greenstein J. I., Haley A. S., Hirsch R. L., Kleiner J. E., Kofie V. Y. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol. 1986 Dec;43(12):1239–1246. doi: 10.1001/archneur.1986.00520120023011. [DOI] [PubMed] [Google Scholar]
  3. Hirsch R. L., Panitch H. S., Johnson K. P. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol. 1985 Nov;5(6):386–389. doi: 10.1007/BF00915335. [DOI] [PubMed] [Google Scholar]
  4. Huber M., Bamborschke S., Assheuer J., Heiss W. D. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol. 1988 Jan;235(3):171–173. doi: 10.1007/BF00314311. [DOI] [PubMed] [Google Scholar]
  5. Jacobs L., Salazar A. M., Herndon R., Reese P. A., Freeman A., Josefowicz R., Cuetter A., Husain F., Smith W. A., Ekes R. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet. 1986 Dec 20;2(8521-22):1411–1413. doi: 10.1016/S0140-6736(86)92730-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Knobler R. L., Panitch H. S., Braheny S. L., Sipe J. C., Rice G. P., Huddlestone J. R., Francis G. S., Hooper C. K., Kamin-Lewis R. M., Johnson K. P. Systemic alpha-interferon therapy of multiple sclerosis. Neurology. 1984 Oct;34(10):1273–1279. doi: 10.1212/wnl.34.10.1273. [DOI] [PubMed] [Google Scholar]
  7. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  8. Ling P. D., Warren M. K., Vogel S. N. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol. 1985 Sep;135(3):1857–1863. [PubMed] [Google Scholar]
  9. McDonald W. I., Halliday A. M. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977 Jan;33(1):4–9. [PubMed] [Google Scholar]
  10. Merrill J. E., Gerner R. H., Myers L. W., Ellison G. W. Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 1. Association between amount of prostaglandin produced, natural killer, and endogenous interferon. J Neuroimmunol. 1983 Jun;4(3):223–237. doi: 10.1016/0165-5728(83)90037-1. [DOI] [PubMed] [Google Scholar]
  11. Neighbour P. A., Miller A. E., Bloom B. R. Interferon responses of leukocytes in multiple sclerosis. Neurology. 1981 May;31(5):561–566. doi: 10.1212/wnl.31.5.561. [DOI] [PubMed] [Google Scholar]
  12. Neighbour P. A. Studies of interferon production and natural killing by lymphocytes from multiple sclerosis patients. Ann N Y Acad Sci. 1984;436:181–191. doi: 10.1111/j.1749-6632.1984.tb14789.x. [DOI] [PubMed] [Google Scholar]
  13. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  14. Salmaggi A., LaMantia L., Milanese C., Bianchi G., Eoli M., Campi A., Nespolo A. CSF T-cell subsets in multiple sclerosis: relationship to cerebrospinal fluid myelin basic protein and clinical activity. J Neurol. 1989 Sep;236(6):336–339. doi: 10.1007/BF00314375. [DOI] [PubMed] [Google Scholar]
  15. Vervliet G., Claeys H., Van Haver H., Carton H., Vermylen C., Meulepas E., Billiau A. Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients. J Neurol Sci. 1983 Jul;60(1):137–150. doi: 10.1016/0022-510x(83)90133-8. [DOI] [PubMed] [Google Scholar]
  16. Waksman B. Mechanisms in multiple sclerosis. Nature. 1985 Nov 14;318(6042):104–105. doi: 10.1038/318104a0. [DOI] [PubMed] [Google Scholar]
  17. Wallach D., Fellous M., Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature. 1982 Oct 28;299(5886):833–836. doi: 10.1038/299833a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES